Alacrity Biosciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alacrity Biosciences Inc.
UK Identifies First Recipients Of Future COVID-19 Vaccine
As clinical trials of potential coronavirus vaccines continue, the UK government has drawn up a list of those who should be first in line for vaccination, although it cautions that many unknowns remain in areas such as efficacy, dosing schedules and duration of protection.
Extraordinary Times Call For Exceptional Response From Philips’ Connected Care Chief
Roy Jakobs was appointed internally to head connected care at Philips on 28 January, shortly before COVID-19 forced the first of many lockdowns around the world. The disruption prompted a rapid rethink of priorities, which has shown opportunities for lasting health care system change.
Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.